S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NASDAQ:SRZN

Surrozen (SRZN) Stock Price, News & Analysis

$9.40
+0.07 (+0.75%)
(As of 04/19/2024 ET)
Today's Range
$9.20
$9.50
50-Day Range
$8.75
$15.71
52-Week Range
$4.50
$16.19
Volume
2,045 shs
Average Volume
17,451 shs
Market Capitalization
$19.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Surrozen MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Surrozen in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$3 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($9.19) to ($2.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.20 out of 5 stars

Medical Sector

530th out of 918 stocks

Biological Products, Except Diagnostic Industry

80th out of 151 stocks

SRZN stock logo

About Surrozen Stock (NASDAQ:SRZN)

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.

SRZN Stock Price History

SRZN Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Surrozen Provides Corporate Update on Clinical Programs
3 Biotech Stocks to Watch in November
Surrozen Provides Third Quarter 2023 Financial Results
Surrozen Inc Ordinary Shares SRZN
Surrozen GAAP EPS of -$0.31
See More Headlines
Receive SRZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/19/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SRZN
Fax
N/A
Employees
74
Year Founded
N/A

Profitability

Net Income
$-43,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.50 million
Book Value
$18.60 per share

Miscellaneous

Free Float
1,325,000
Market Cap
$19.03 million
Optionable
Not Optionable
Beta
0.74
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Craig C. Parker M.B.A. (Age 62)
    CEO, President & Director
    Comp: $753.3k
  • Mr. Charles Williams (Age 43)
    CFO, COO & Corporate Secretary
    Comp: $563.49k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisor
  • Dr. Roeland Nusse Ph.D. (Age 74)
    Co-Founder & Member of Scientific Advisor
  • Dr. Calvin Kuo M.D.
    Ph.D., Co-Founder & Member of Scientific Advisor
  • Dr. Li Yang Ph.D.
    Executive Vice President of Research
  • Esther Jhun
    Controller

SRZN Stock Analysis - Frequently Asked Questions

How have SRZN shares performed in 2024?

Surrozen's stock was trading at $9.40 at the start of the year. Since then, SRZN shares have increased by 0.1% and is now trading at $9.41.
View the best growth stocks for 2024 here
.

Are investors shorting Surrozen?

Surrozen saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 7,900 shares, an increase of 132.4% from the March 15th total of 3,400 shares. Based on an average daily trading volume, of 17,800 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.6% of the company's shares are sold short.
View Surrozen's Short Interest
.

When is Surrozen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SRZN earnings forecast
.

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) released its quarterly earnings data on Monday, November, 15th. The company reported ($7.65) EPS for the quarter, missing the consensus estimate of ($5.85) by $1.80.

When did Surrozen's stock split?

Surrozen's stock reverse split on Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRZN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners